Innovative medical technologies for the treatment of urinary tract infections in peri- and postmenopausal women




uncomplicated urinary tract infections, treatment, perimenopause, postmenopause


Objectives: to evaluate the effectiveness of Utipro Plus AF for uncomplicated urinary tract infections in women in the peri- and postmenopausal period.
Materials and methods. The study included 45 patients aged 48–70 years with verified uncomplicated urinary tract infection. All patients received antimicrobial agents in accordance with approved guidelines. 25 women (main group) also received Utipro Plus AF, 20 women (control group) received only antimicrobial agents. The effectiveness of treatment was assessed on the 6th, 11th, 30th and 75th day of observation. Efficiency criteria were a decrease in the intensity of clinical symptoms, a decrease in the number of relapses, and bacterial sanitation based on the results of urine cultures (≤ 103 CFU/ml).
Results. Clinical picture changed dramatically in the patients of the examined groups after treatment. Main group had no urinary incontinence, imperative urges to urinate, the frequency of dysuria disorders decreased by three times in this group, pain in the lower abdomen and burning sensation during urination were 5 times less common.
Recurrences of urinary tract infections were noted in both groups by bacteriological and symptomatic criteria, but their frequency was much lower in the group that received Utipro Plus AF in addition to antibiotics. The number of positive results of urine cultures on the 75th day of observation decreased to 16% in the main group, and to 65% in the control group.
Recurrences of urinary tract infections according to clinical criteria on the 75th day of observation were verified in 3 patients of the main group and in 12 patients in the control group.
Conclusions. The medical product Utipro Plus AF effectively reduces bacteriological and clinical signs of uncomplicated urinary tract infections, which makes its use advisable as an additional agent to antibiotic therapy in women with uncomplicated urinary tract infections in peri- and postmenopausal period.

Author Biography

О.V. Kravchenko, Higher State Educational Institution of Ukraine “Bukovinian State Medical University”, Chernivtsi

MD, professor, head of Obstetrics, Gynecology and Perinatology Department


  1. Efimenko, O.A. “Climacteric disorders: in the center of attention – the early beginning of pathogenetic therapy.” Health of Ukraine. Thematic issue “Gynecology. Obstetrics. Reproductology” 2.30 (2018): 20–21.
  2. Yefimenko, O.O., Zanko, O.V. “Menopause: focus on additional possibilities of therapy. Literature review.” Reproductive endocrinology 3.53 (2020): 62–8. DOI: 10.18370/2309-4117.2020.53.62-68
  3. Yefimenko, O.O. Prevention, diagnosis and treatment of perimenopausal disorders in women: Thesis for the doctor’s degree of medical sciences: special. 14.01.1 Obstetrics and gynecology. Kyiv (2019): 377.
  4. Korinchuk, M. “Menopause and vaginal microbe: a review of the literature.” Health of Ukraine 1.25 (2017): 3–5.
  5. Yankovsky, D.S., Shirobokov, V.P., Antypkin, Y.G., et al. “Microbiome and women’s health.” Reproductive endocrinology 4 (2015): 13–28.
  6. Nagorna, V.F. “Modern ideas about the vaginal microbiota.” Obstetrics. Gynecology. Genetics 4.1 (2018): 5–12.
  7. Rogovskaya, S.I., Gomberg, M.A. “Dynamic changes in the microecosystem of the vagina and treatment of vaginal infections.” StatusPraesens 4 (2019).
  8. Zaychenko, G.V., Sinitsyna, О.S., Karpenko, N.O., et al. “Disorders of women’s health due to age-related estrogen deficiency and their correction (literature review).” Journal of the National Amy of cadeMedical Sciences of Ukraine 25.2 (2019): 211–21.
  9. Beerepoot, M., Geerlings, S. “Non-antibiotic prophylaxis for urinary tract infections.” Pathogens 5.2 (2016): 36. DOI: 10.3390/pathogens5020036
  10. Chakalova, G. “Utipro plus capsule, a new innovative approach for the treatment of cystitis and other bacterial urinary tract infections.”Akush Ginekol (Sofiia) 55.1.2 (2016): 23–5.
  11. Danielsson, D., Teigen, P.K, Moi, H. “The genital econiche: focus on microbiota and bacterial vaginosis.” Ann N Y Acad Sci 1230.1 (2011): 48–58. DOI: 10.1111/j.1749-6632.2011.06041.x
  12. De Servi, B., Ranzini, F, Piqu’e, N. “Effect of Utipro(®) (containing gelatin-xyloglucan) against Escherichia coli invasion of intestinal epithelial cells: results of an in vitro study.” Future Microbiol 11.5 (2016): 651–8. DOI: 10.2217/fmb-2016-0022
  13. Olier, M., Sekkal, S., Harkat, C., et al. “Evaluation of reticulated gelatin-hibiscus-propolis against intestinal commensal species commonly associated with urinary tract infections.” Future Microbiol 12.6 (2017): 505–13. DOI: 10.2217/fmb-2016-0175
  14. Betschart, C., Albrich, W.C., Brandner, S., et al. “Guideline of the Swiss Society of Gynaecology and Obstetrics (SSGO) on acute and recurrent urinary tract infections in women, including pregnancy.” Swiss Med Wkly 150 (2020): w20236. DOI: 10.4414/smw.2020.20236
  15. Cai, T., Tiscione, D., Cocci, A., et al. “Hibiscus extract, vegetable proteases and Commiphora myrrha are useful to prevent symptomatic UTI episode in patients affected by recurrent uncomplicated urinary tract infections.” Arch Ital Urol Androl 90.3 (2018): 203–7. DOI: 10.4081/aiua.2018.3.203
  16. Liu, H.T., Lin, Н., Kuo, Н.С. “Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.” Neurourology and urodynamics 30.8 (2011): 1525–9. DOI: 10.1002/nau.21118
  17. Medina, M., Castillo-Pino, E. “An introduction to the epidemiology and burden of urinary tract infections.” Ther Adv Urol 11 (2019). DOI: 10.1177/1756287219832172
  18. Mirmonsef, Р., Hotton, A.L., Gilbert, D., et al. “Free glycogen in vaginal fluids is associated with Lactobacillus colonization and low vaginal pH.” PloS One 9.7 (2014). DOI: 10.1371/journal.pone.0102467
  19. Pinkerton, J.V. “Hormone Therapy for Postmenopausal Women.” N Engl J Med 382.5 (2020): 446–55. DOI: 10.1056/NEJMcp1714787
  20. Birkhaeuser, M., Genazzani, A.R. Pre-menopause. Menopause and Beyond. Volume 5: Frontiers in Gynecological Endocrinology. Springer (2018): 327 р. DOI: 10.1007/978-3-319-63540-8
  21. Stange, R., Schneider, B., Albrecht, U., et al. “Results of a randomized, prospective, double-dummy, double-blind trial to compare efficacy and safety of a herbal combination containing Tropaeoli majoris herba and Armoraciae rusticanae radix with cotrimoxazole in patients with acute and uncomplicated cystitis.” Res Rep Urol 9 (2017): 43–50. DOI: 10.2147/RRU.S121203
  22. Storme, O., Tiran Saucedo, J., Garcia-Mora, A., et al. “Risk factors and predisposing conditions for urinary tract infection.” Ther Adv Urol 11 (2019). DOI: 10.1177/1756287218814382
  23. Gass, M., Larson, J., Cochrane, B., et al. “Sexual activity and vaginal symptoms in the postintervention phase of the Women’s Health Initiative Hormone Therapy Trials.” Menopause 25 (2018): 252–64. DOI: 10.1097/GME.0000000000000994
  24. Edwards, H., Duchesne, A., Au, A.S., Einstein, G. “The Many Menopauses: Searching the Cognitive Research Literature for Menopause Types.” Menopause 26.1 (2019): 45–65. DOI: 10.1097/GME.0000000000001171
  25. Fraile, B., Alcover, J., Royuela, M., et al. “Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies.” Future Microbiol 12.8 (2017): 721–31. DOI: 10.2217/fmb-2017-0015
  26. Cai, T., Tamanini, I., Cocci, A., et al. “Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study.” Future Microbiol 14.12 (2019): 1013–20. DOI: 10.2217/fmb-2019-0145



How to Cite

Kravchenko О. (2022). Innovative medical technologies for the treatment of urinary tract infections in peri- and postmenopausal women. REPRODUCTIVE ENDOCRINOLOGY, (65), 97–100.



Management of menopause